You are here: Industry Insights > Genentech

News List

Genentech receives FDA approval for Polivy to treat DLBCL pharmaceutical-technology
June 13, 2019
Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for the use of Polivy (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab (BR) to treat diffuse large B-cell lymphoma (DLBCL) in adults.
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma drugs
June 11, 2019
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma.
Genentech Announces FDA Approval for Venclexta Plus Gazyva for People with CLL americanpharmaceuticalreview
May 23, 2019
Genentech announced the U.S. Food and Drug Administration (FDA) has approved Venclexta? (venetoclax) in combination with Gazyva? (obinutuzumab) for the treatment of people with ...
Parvus and Genentech to develop treatment options in gastroenterology pharmaceutical-technology
May 22, 2019
Biopharmaceutical firm Parvus Therapeutics has signed a worldwide collaboration and licence agreement with Genentech to develop, manufacture and commercialise therapeutics?for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD) and?coeliac d
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech pharmafocusasia
March 12, 2019
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer.
Genentech gets FDA priority review for two cancer drugs pharmaceutical-technology
February 20, 2019
Genentech, a subsidiary of Roche, has secured priority review status from the US Food and Drug Administration (FDA) for two of its oncology drugs, entrectinib and polatuzumab vedotin.
PhRMA Welcomes Genentech and Gilead Sciences to Association americanpharmaceuticalreview
January 21, 2019
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Genentech, a member of the Roche Group, and Gilead Sciences have joined the association as members....
Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech to Develop Personalized Cellular Therapies pharmafocusasia
January 08, 2019
Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech....
Proteostasis Therapeutics Announces Global License Agreement with Genentech americanpharmaceuticalreview
December 18, 2018
Proteostasis Therapeutics announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group...
M&As this week: Sun Pharma, Genentech, CVS Health pharmaceutical-technology
December 03, 2018
Sun Pharma?has signed a definitive agreement to acquire Pola Pharma for $1m.Genentech?has entered a definitive agreement to acquire Jecure Therapeutics.....